## **Boston Scientific Announces Results For Third Quarter 2016**

MARLBOROUGH, Mass., Oct. 26, 2016 [PRNewswire] -- Boston Scientific Corporation (NYSE: BSX) generated sales of \$2.105 billion during the third quarter ended September 30, 2016, compared to the company's guidance range for the quarter of \$2.035 to \$2.085 billion. This represents growth of 11 percent on a reported basis and 10 percent on an operational basis (calculated on a constant currency basis), all compared to the prior year period. The company reported GAAP earnings of \$228 million, or \$0.17 per share, compared to a loss of \$(0.15) a year ago, and achieved adjusted earnings per share of \$0.27 for the period, compared to \$0.24 a year ago.

"Our differentiated products and services continue to make a meaningful impact for our customers and the patients they treat, as shown by very strong revenue growth in the third quarter and year to date," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "Our global team is delivering excellent performance across our various business units and geographies."

#### Third quarter financial results and recent developments:

- Reported third quarter sales of \$2.105 billion, representing an increase of 11 percent on a reported basis and 10 percent on an operational basis, all compared to the prior year period.
- Grew organic revenue 9 percent in the third quarter over the prior year period. Organic revenue growth excludes the impact of
  changes in foreign currency exchange rates and sales from the acquisition of the American Medical Systems (AMS) male urology
  portfolio for the month of July.
- Reported GAAP earnings of \$0.17 per share compared to the company's guidance range of \$0.13 to \$0.15 per share. Achieved adjusted earnings per share of \$0.27 compared to the guidance range of \$0.25 to \$0.27 per share.
- · Achieved third quarter revenue growth in all segments, all compared to the prior year period:
  - MedSurg: 15 percent (14 percent operational and 10 percent organic)
  - Cardiovascular: 13 percent (12 percent operational and organic)
  - Rhythm Management: 4 percent (3 percent operational and organic)
- Delivered strong regional revenue growth, all compared to the prior year period:
  - U.S.: 11 percent (11 percent operational and 9 percent organic)
  - Europe: 6 percent (7 percent operational and 5 percent organic)
  - AMEA (Asia-Pacific, Middle East and Africa): 20 percent (12 percent operational and organic)
  - Emerging markets:\* 10 percent (19 percent operational and organic)
- Entered into a definitive agreement and commenced a cash tender offer to acquire EndoChoice Holdings, Inc. (NYSE: GI), which offers physicians a broad portfolio of products to treat gastrointestinal conditions, for approximately \$210 million.
- Launched the Resolution 360™ Hemoclip, designed to offer gastroenterologists greater control when performing hemostatic clipping, used in endoscopic procedures of the upper and lower gastrointestinal (GI) tract to stop and help prevent bleeding that occurs with conditions including peptic ulcers, polyps removed during a colonoscopy and diverticulosis of the colon.
- Received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted EMBLEM S-ICD Systems. United Healthcare, the largest private healthcare insurer in the U.S., also now covers the EMBLEM S-ICD System for a subset of patients indicated for implantable cardioverter-defibrillator (ICD) therapy. As a result, an estimated 91 percent of the insured U.S. residents now has access through Medicare, Medicaid or their private health plan.
- Received CE Mark for the LOTUS Edge<sup>™</sup> Valve System<sup>\*\*</sup>, the company's next-generation transcatheter aortic valve replacement (TAVR) technology.
- Announced data from the MAJESTIC trial of the Eluvia™ Drug-Eluting Vascular Stent System\*\*\* demonstrating 92.5% freedom
  from total lesion revascularization (FTLR) at two years, at the annual meeting of the Cardiovascular and Interventional Radiology
  Society of Europe (CIRSE). Also at CIRSE, unveiled data from the All-Comer Registry for the Ranger Drug-Coated Balloon
  Catheter\*\* confirming the benefit of an efficient-release drug coated balloon (DCB) in long lesions by achieving 91.9% FTLR rate at
  six months.
- Made a \$25 million strategic investment in VENITI Inc., a maker of stents for chronic venous insufficiency, which affects more than 20 million adults across the United States and Europe.

<sup>\*</sup> We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic

conditions, healthcare sectors and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets.

\*\* The LOTUS Edge™ Valve System and Ranger™ Drug-Coated Balloon Catheter are not available for use or sale in the U.S.

\*\*\* In the U.S., the Eluvia™ Drug-Eluting Vascular Stent System is an investigational device, limited by federal law to investigational use only.

#### Net sales for the third quarter:

					Change							
		Three Mo Septe						Less:	Impact	of		stant
in millions		2016		2015	As Repor	ted Basis	F	oreign	Curre	ncy	Ва	sis
Interventional Cardiology	\$	568	\$	500	14	%	\$	(1)	1	%	13	%
Peripheral Interventions	-	257	•	227	12	%	-	Ì3	1	%	11	%
Cardiovascular		825		727	13	%		2	1	%	12	%
Cardiac Rhythm Management		467		451	4	%		1	1	%	3	%
Electrophysiology		60		57	5	%		0	0	%	5	%
Rhythm Management		527		508	4	%		1	1	%	3	%
Endoscopy		367		331	11	%		5	2	%	9	%
Urology and Pelvic Health		248		198	26	%		(3)	0	%	26	%
Neuromodulation		138		124	11	%		(1)	(1)	%	12	%
MedSurg		753		653	15	%		1	1	%	14	%
Net Sales	\$	2,105	\$	1,888	11	%	\$	4	1	%	10	%

<sup>\*</sup>Urology and Pelvic Health grew 13% on an organic basis.

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Sales growth rates that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales are not prepared in accordance with U.S. GAAP. An explanation of the company's use of these non-GAAP financial measures is included in the exhibits attached to this news release.

On a consolidated GAAP basis, net income for the third quarter of 2016 was\$228 million, or \$0.17 per share. These results included an intangible asset impairment charge, acquisition-related net credits, restructuring and restructuring-related net charges, litigation-related net charges and amortization expense, of \$140 million (after-tax) or \$0.10 per share. Adjusted net income for the third quarter of 2016, excluding these net charges, was \$368 million, or \$0.27 per share.

On a consolidated GAAP basis, net loss for the third quarter of 2015 was\$198 million, or \$(0.15) per share. These results included intangible asset impairment charges, acquisition-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, pension termination charges and amortization expense, of \$524 million (after-tax) or \$0.39 per share. Adjusted net income for the third quarter of 2015, excluding these net charges, was \$326 million, or \$0.24 per share.

# **Guidance for Full Year and Fourth Quarter 2016**

The company now estimates revenue for the full year 2016 to be in a range of \$8.335 to \$8.385 billion (compared to prior guidance of \$8.270 to \$8.370 billion), which versus the prior year period represents growth of approximately 11 to 12 percent on a reported basis, growth of approximately 12 percent on an operational basis, and growth of approximately 9 percent on an organic basis. The company now estimates income on a GAAP basis in a range of \$0.32 to \$0.34 per share (compared to prior guidance of \$0.30 to \$0.35 per share), and now estimates adjusted earnings, excluding intangible asset impairment charges, acquisition-related net charges, litigation-, and restructuring and restructuring-related net charges, and amortization expense, in a range of \$1.09 to \$1.11 per share (compared to prior guidance of \$1.07 to \$1.11 per share).

The company estimates sales for the fourth quarter of 2016 to be in a range of \$2.140 to \$2.190 billion, which versus the prior year period represents growth of approximately 8 to 11 percent on a reported basis, and growth of approximately 7 to 9 percent on an operational basis. The company estimates earnings on a GAAP basis in a range of \$0.15 to \$0.17 per share. Adjusted earnings, excluding acquisition-related net charges, restructuring and restructuring-related net charges and amortization expense, are estimated in a range of \$0.27 to \$0.29 per share.

## **Conference Call Information**

Boston Scientific management will be discussing these results with analysts on a conference call today a8:00 a.m. (ET). The company will webcast the call to interested parties through its website: <a href="www.bostonscientific.com">www.bostonscientific.com</a>. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

#### **About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit <a href="www.bostonscientific.com">www.bostonscientific.com</a> and connect on Twitter and Facebook.

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, organic and operational revenue growth rates, GAAP earnings and adjusted earnings for the fourth quarter and full year 2016; our financial performance; our business plans; and our positioning for revenue and earnings growth. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

#### **Use of Non-GAAP Financial Information**

A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.

CONTACT:

Media: Tom Keppeler

508-683-6585 (office) Media Relations

Boston Scientific Corporation tom.keppeler@bsci.com

Investors: Susan Lisa, CFA

508-683-5565 (office) Investor Relations

Boston Scientific Corporation <a href="mailto:investor\_relations@bsci.com">investor\_relations@bsci.com</a>

# BOSTON SCIENTIFIC CORPORATION O CONSOLIDATED GAAP RESULTS OF OPERAT

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS (Unaudited)

	Three Mo Septe	 		Nine Months Ende September 30,			
in millions, except per share data	 2016	2015		2016		2015	
Net sales	\$ 2,105	\$ 1,888	\$	6,195	\$	5,499	
Cost of products sold	594	539		1,805		1,600	
Gross profit	 1,511	1,349	-	4,390		3,899	

Operating expenses:									
Selling, general and administrative expenses		772		729		2,268		2,095	
Research and development expenses		232		221		664		632	
Royalty expense		20		17		59		53	
Amortization expense		136		131		408		361	
Intangible asset impairment charges		7		10		7		19	
Contingent consideration expense (benefit)		(13)		40		23		86	
Restructuring charges		5		7		22		16	
Litigation-related charges (credits)		4		457		632		649	
Pension termination charges		_		36		_		44	
		1,163		1,648		4,083		3,955	_
Operating income (loss)		348		(299)		307		(56)	_
Other income (expense):									
Interest expense		(58)		(58)		(175)		(225)	
Other, net		(33)		(10)		(44)		(31)	
Income (loss) before income taxes		257		(367)		88		(312)	_
Income tax expense (benefit)		29		(169)		(135)		(215)	
Net income (loss)	\$	228	\$	(198)	\$	223	\$	(97)	_
Net income (loss) per common share - basic	\$	0.17	\$	(0.15)	\$	0.16	\$	(0.07)	
Net income (loss) per common share - assuming dilution	\$	0.17	\$	(0.15)	\$	0.16	\$	(0.07)	
Weighted-average shares outstanding									
Basic	1	,360.6		1,344.0	1	,356.1	1	1,339.7	
Assuming dilution	1	,379.7	•	1,344.0	1	,374.9	1	1,339.7	

# BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

	A	As of							
	September 30,	December 31,							
in millions, except share data	2016	2015							
	(Unaudited)								
ASSETS									
Current assets:	Φ 007	Φ 040							
Cash and cash equivalents	\$ 237	\$ 319							
Trade accounts receivable, net	1,385	1,275							
Inventories	998 84	1,016 496							
Deferred and prepaid income taxes	04	490							
Other current assets	477	365							
Total current assets	3,181	3,471							
Property, plant and equipment, net	1,500	1,490							
Goodwill	6,498	6,473							
Other intangible assets, net	5,838	6,194							
Other long-term assets	680	505							
TOTAL ASSETS	\$ 17,697	\$ 18,133							
LIABILITIES AND STOCKHOLDERS' EQUITY									
Current liabilities:									
Current debt obligations	\$ 254	\$ 3							
Accounts payable	298	209							
Accrued expenses	2,099	1,970							
Other current liabilities	365	248							
Total current liabilities	3,016	2,430							
Long-term debt	5,171	5,674							
Deferred income taxes	26	735							
Other long-term liabilities	3,002	2,974							

Commitments and contingencies

Stockholders' equity Preferred stock, \$.01 par value - authorized 50,000,000 shares, none issued and outstanding Common stock, \$.01 par value - authorized 2,000,000,000 shares issued 1,609,010,333 shares as of September 30, 2016 and 1,594,213,786 shares as of December 31, 2015 19 16 Treasury stock, at cost - 247,566,270 shares as of September 30, 2016 and December 31, 2015 (1,717)(1,717)Additional paid-in capital 16,985 16,860 Accumulated deficit (8,706)(8.927)Accumulated other comprehensive income (loss), net of tax (99)88 Total stockholders' equity 6.482 6,320 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 17,697 18,133

#### **BOSTON SCIENTIFIC CORPORATION**

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (Unaudited)

	Three Months Ended September 30, 2016										
			Tax			lm	pact per				
in millions, except per share data	Pre-T	ax I	mpact (a)	Af	ter-Tax		Share				
GAAP net income (loss)	\$ 25	57 \$	(29)	\$	228	\$	0.17				
Non-GAAP adjustments:											
Intangible asset impairment charge		7	(1)		6		0.00				
Acquisition-related net credits (b)		1)	(1)		(2)		(0.00)				
Restructuring and restructuring-related net charges (c)		17	(4)		13		0.01				
Litigation-related net charges		4	(1)		3		0.00				
Amortization expense	1;	36	(16)		120		0.09				
Adjusted net income	\$ 42	20 \$	5 (52)	\$	368	\$	0.27				

	Th	ree Months Ende	ed September 30	, 2015
in millions, except per share data	Pre-Tax	Tax Impact (a)	After-Tax	Impact per Share
GAAP net income (loss)	\$ (367)	\$ 169	\$ (198)	\$ (0.15)
Non-GAAP adjustments:				
Intangible asset impairment charges	10	(1)	9	0.01 *
Acquisition-related net charges (d)	80	(12)	68	0.05 *
Restructuring and restructuring-related net charges (e)	21	(3)	18	0.01 *
Litigation-related net charges	457	(165)	292	0.22 *
Pension termination charges	36	(13)	23	0.02 *
Amortization expense	131	(17)	114	0.08 *
Adjusted net income	\$ 368	\$ (42)	\$ 326	\$ 0.24

- \*Assumes dilution of 20.2 million shares for the three months ended September 30, 2015 for all or a portion of these non-GAAP Adjustments
- (a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
- (b) In the third quarter of 2016, pre-tax acquisition-related net credits were \$1 million, of which \$7 million was recorded in cost of products sold, \$5 million of was recorded in selling, general and administrative expenses, and \$13 million was recorded as a benefit to contingent consideration.
- (c) In the third quarter of 2016, pre-tax restructuring charges were \$5 million and pre-tax restructuring-related charges were \$12 million, of which \$8 million was recorded in cost of products sold and \$4 million was recorded in selling, general and administrative expenses.
- (d) In the third quarter of 2015, pre-tax acquisition-related net charges were \$80 million, of which \$16 million was recorded in cost of products sold, \$23 million was recorded in selling, general and administrative expenses, \$1 million was recorded in research and development, and \$40 million was recorded as contingent consideration expense.
- (e) In the third quarter of 2015, pre-tax restructuring charges were \$7 million and pre-tax restructuring-related charges were \$14 million, of which \$5 million was recorded in cost of products sold and \$9 million was recorded in selling, general and administrative expenses.

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

Nine Months Ended September 30, 2016

				Tax			lm	pact per
in millions, except per share data		re-Tax	lm	pact (a)	Af	ter-Tax		Share
GAAP net income (loss)	\$	88	\$	135	\$	223	\$	0.16
Non-GAAP adjustments:								
Intangible asset impairment charge		7		(1)		6		0.00
Acquisition-related net charges (b)		93		(3)		90		0.07
Restructuring and restructuring-related net charges (c)		55		(13)		42		0.03
Litigation-related net charges		632		(228)		404		0.29
Amortization expense		408		(54)		354		0.26
Adjusted net income	\$	1,283	\$	(164)	\$	1,119	\$	0.81

Nine Months Ended September 30, 2015

in millions, except per share data	-	Pre-Tax	lm	Tax pact (a)	Af	ter-Tax	In	npact per Share	
GAAP net income (loss)	\$	(312)	\$	215	\$	(97)	\$	(0.07)	
Non-GAAP adjustments:									
Intangible asset impairment charges		19		(3)		16		0.01	*
Acquisition-related net charges (d)		169		(17)		152		0.11	*
Restructuring and restructuring-related net charges (e)		58		(10)		48		0.04	*
Litigation-related net charges		649		(235)		414		0.31	*
Debt extinguishment charges (f)		45		(16)		29		0.02	*
Pension termination charges		44		(16)		28		0.02	*
Amortization expense		361		(46)		315		0.23	*
Adjusted net income	\$	1,033	\$	(128)	\$	905	\$	0.67	_

- \*Assumes dilution of 21.5 million shares for the nine months ended September 30, 2015 for all or a portion of these non-GAAP Adjustments
- (a) Amounts are tax effected at the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate."
- (b) In the first nine months of 2016, pre-tax acquisition-related net charges were \$93 million, of which \$39 million was recorded in cost of products sold, \$31 million was recorded in selling, general and administrative expenses, and \$23 million was recorded as contingent consideration expense.
- (c) In the first nine months of 2016, pre-tax restructuring charges were \$22 million and pre-tax restructuring-related charges were \$33 million, of which \$20 million was recorded in cost of products sold and \$13 million was recorded in selling, general and administrative expenses.
- (d) In the first nine months of 2015, pre-tax acquisition-related net charges were \$169 million, of which \$24 million were recorded in cost of products sold, \$36 million was recorded in selling, general and administrative expense, \$19 million was recorded in research and development, \$86 million was recorded as a contingent consideration expense, and \$4 million was recorded as interest expense.
- (e) In the first nine months of 2015, pre-tax restructuring charges were \$16 million and pre-tax restructuring-related charges were \$42 million, of which \$20 million was recorded in cost of products sold and \$22 million was recorded in selling, general and administrative expenses.
- (f) Debt extinguishment charges are recorded in interest expense.

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

# **BOSTON SCIENTIFIC CORPORATION**

SEGMENT INFORMATION (Unaudited)

SEGMENT NET SALES*	Three Months Ended September 30,							Nine Months Ended September 30,						
in millions	 2016		2015	Chai	nge		2016		2015	Change				
Interventional Cardiology Peripheral Interventions	\$ 620 273	\$	551 246	13 11	% %	\$	1,870 815	\$	1,659 723	13 % 13 %				

Cardiovascular	893	797	12	%	2,685	2,382	13	%
Cardiac Rhythm Management	498	483	3	%	1,481	1,456	2	%
Electrophysiology	64	61	5	%	192	182	5	%
Rhythm Management	562	544	3	%	1,673	1,638	2	%
Endoscopy	393	362	9	%	1,148	1,042	10	%
Urology and Pelvic Health	260	207	26	%	773	479	61	%
Neuromodulation	143	128	12	%	407	369	11	%
MedSurg	796	697	14	%	2,328	1,890	23	%
Subtotal Core Businesses	2,251	2,038	10	%	6,686	5,910	13	%
Foreign Currency	(146)	(150)	N/A		(491)	(411)	N/A	
Net Sales	\$ 2,105	\$ 1,888	11	%	\$ 6,195	\$ 5,499	13	%

Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

SEGMENT OPERATING INCOME*		onths Ended ember 30,	Nine Months Ended September 30,			
in millions	2016	2015	2016	2015		
Segment operating income						
Cardiovascular	\$ 292	\$ 249	\$ 885	\$ 732		
Rhythm Management	113	97	300	252		
MedSurg	262	235	763	590		
Operating income allocated to reportable segments	667	581	1,948	1,574		
Corporate expenses and currency exchange	(156)	(145)	(446)	(334)		
Intangible asset impairment charges; acquisition-related net						
charges and credits; restructuring- and restructuring-related net						
charges; litigation-related net charges and credits; and pension						
termination charges	(27)	(604)	(787)	(935)		
Amortization expense	(136)	(131)	(408)	(361)		
Operating income (loss)	\$ 348	\$ (299)	\$ 307	\$ (56)		

<sup>\*</sup>We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency. Sales generated from reportable segments, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-operational, such as amounts related to intangible asset impairment charges; acquisition-related net charges and credits; restructuring- and restructuring-related net charges; litigation-related net charges and credits; pension termination charges; and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.

#### **BOSTON SCIENTIFIC CORPORATION**

WORLDWIDE CARDIAC RHYTHM MANAGEMENT (CRM) SALES BY COMPONENT (Unaudited)

# Three Months Ended September 30,

(in millions)		2016	2015
Defibrillator systems	<u> </u>	311	 326
Pacemaker systems		156	125
CRM products	\$	467	\$ 451

# Nine Months Ended September 30,

(in millions)	2016	2015
Defibrillator systems	956	996
Pacemaker systems	422	371
CRM products	\$ 1,378	\$ 1,367

#### **BOSTON SCIENTIFIC CORPORATION**

SEGMENT AND REGIONAL NET SALES (Unaudited)

## Q3 2016 Segment Net Sales as compared to Q3 2015

					Rhy:	thm			
	Med	Surg	Cardiov	ascular	Manag	ement	Total	BSC	
Percentage change in net sales, as reported	15	%	13	%	4	%	11	%	
Less: Impact of Foreign Currency Fluctuations	1	%	1	%	1	%	1	%	
Percentage change in net sales, constant currency	14	%	12	%	3	%	10	%	
Less: Impact of AMS acquisition	4	%	0	%	0	%	1	%	
Percentage change in net sales, organic	10	%	12	%	3	%	9	%	

# Q3 2016 Regional Net Sales as compared to Q3 2015

	U.	S.	Eur	оре	АМ	EA	Emer Marl	-	
Percentage change in net sales, as reported	11	%	6	%	20	%	10	%	_
Less: Impact of Foreign Currency Fluctuations	0	%	(1)	%	8	%	(9)	%	
Percentage change in net sales, constant									_
currency	11	%	7	%	12	%	19	%	
Less: Impact of AMS acquisition	2	%	2	%	0	%	0	%	
Percentage change in net sales, organic	9	%	5	%	12	%	19	%	_

# Q3 2016 Urology and Pelvic Health Net Sales as compared to Q3 2015

	Urolog Pelvic	•
Percentage change in net sales, as reported	26	%
Less: Impact of Foreign Currency Fluctuations	0	%
Percentage change in net sales, constant		
currency	26	%
Less: Impact of AMS acquisition	13	%
Percentage change in net sales, organic	13	%

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

#### **BOSTON SCIENTIFIC CORPORATION**

ESTIMATED REVENUE NON-GAAP GROWTH RATES AND NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS
(Unaudited)

# Q4 and Full Year 2016 Estimated Revenue Growth Rates

	Q4 2016	Estimate	Full Year 2016 Estimate		
	(Low)	(High)	(Low)	(High)	
Estimated GAAP sales growth	8 %	11 %	11 %	12 %	
Less: Estimated Impact of Foreign Currency Fluctuations	1 %	2 %	(1) %	0 %	
Estimated sales growth, constant currency	7 %	9 %	12 %	12 %	

N/A		N/A		3	%	3 9	%
7	%	9	%	9	%	9 (	%

#### Q4 and Full Year 2016 EPS Guidance

	Q4 2016 Estimate		Full Year 2016 Estimate		Prior Full Year 2016 Estimate	
	(Low)	(High)	(Low)	(High)	(Low)	(High)
GAAP results	\$ 0.15	\$ 0.17	\$ 0.32	\$ 0.34	\$ 0.30	\$ 0.35
Intangible asset impairment charges	_	_	0.00	0.00	_	_
Estimated acquisition-related net charges	0.01	0.01	0.07	0.07	0.08	0.08
Estimated restructuring and restructuring-related charges	0.03	0.03	0.07	0.07	0.06	0.05
Estimated amortization expense	0.08	0.08	0.34	0.34	0.34	0.34
Litigation-related charges	_	_	0.29	0.29	0.29	0.29
Adjusted results	\$ 0.27	\$ 0.29	\$ 1.09	\$ 1.11	\$ 1.07	\$ 1.11

An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.

#### **Use of Non-GAAP Financial Measures**

To supplement our financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts, and adjusted net sales that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

The GAAP financial measure most directly comparable to adjusted net income is GAAP net income and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income per share. To calculate adjusted net sales that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The GAAP financial measure most directly comparable to this constant currency growth rate and/or growth rates excluding the impacts of recent acquisitions with significant sales is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. With the exception of the impact of recent acquisitions with significant sales, the adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures that are reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income and adjusted net income per share that exclude certain amounts, and adjusted net sales that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures for the three and nine months ended September 30, 2016 and 2015, and for the forecasted three month period and full year ending December 31, 2016, as well as reasons for excluding each of these individual items:

Adjusted Net Income and Adjusted Net Income per Share:

Intangible asset impairment charges - This amount represents write-downs of certain intangible asset balances in the first nine
months of 2016 and 2015. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist
or a change in circumstances has occurred that would indicate impairment and test our indefinite-lived intangible assets at least
annually for impairment. If we determine the carrying value of the amortizable intangible asset is not recoverable or we conclude
that it is more likely than not that the indefinite-live asset is impaired, we will write the carrying value down to fair value in the period
identified. We exclude the impact of impairment charges from management's assessment of operating performance and from our

operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management has excluded intangible asset impairment charges for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

- Acquisition-related net charges (credits) These adjustments may consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) purchased and/or funded in-process research and development expenses incurred outside of a business combination; and (d) due diligence, other fees, inventory step up amortization, and integration and exit costs. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, other fees, inventory step-up amortization, and integration and exit costs include legal, tax, severance and other expenses associated with prior and potential future acquisitions that can be highly variable and not representative of ongoing operations. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
- Restructuring and restructuring-related net charges (credits) These adjustments represent severance and other direct costs associated with our restructuring programs. These costs are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these costs for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
- Litigation-related net charges (credits) These adjustments include certain significant product liability and other litigation-related charges and credits. These amounts are excluded by management in assessing our operating performance, as well as from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
- <u>Debt extinguishment charges</u> This item represents premiums, accelerated amortization of debt issuance costs and investor discount costs net of interest rate hedge gains related to the early extinguishment of \$1.0 billion of public senior notes during the second quarter of 2015. These adjustments are not expected to recur and do not reflect expected ongoing operating results. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
- Pension termination charges This item represents charges associated with the termination of the Guidant Retirement Plan, a frozen defined benefit plan. These charges are not expected to recur after 2015 and do not reflect expected ongoing operating results. Accordingly, management has excluded these amounts for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.
- Amortization expense We record intangible assets at historical cost and amortize them over their estimated useful lives. Amortization expense is excluded from management's assessment of operating performance and is also excluded from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management has excluded amortization expense for purposes of calculating these non-GAAP financial measures to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Adjusted Net Sales Excluding the Impact of Changes in Foreign Currency Exchange Rates and/or the Impact of Recent Acquisitions with Significant Sales

• The impact of changes in foreign currency exchange rates is highly variable and difficult to predict. The impact of recent acquisitions with significant sales in the current period and no prior period equivalent may distort our presentation of organic growth. Accordingly, management excludes the impact of changes in foreign currency exchange rates and/or the impacts of recent acquisitions with significant sales for purposes of reviewing the net sales and growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Adjusted net income and adjusted net income per share that exclude certain amounts, and adjusted net sales that exclude the impact of changes in foreign currency exchange rates and/or the impacts of recent acquisitions with significant sales, are not in accordance with U.S. GAAP and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

Logo - http://photos.prnewswire.com/prnh/20160203/329537LOGO

SOURCE Boston Scientific Corporation

